Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

Eneida R. Nemecek; Kristin Ellis; Wensheng He; Nancy J. Bunin; Rajinder S. Bajwa; Alexandra Cheerva; Mitchell S. Cairo; Christopher Dvorak; Michel Duval; Stella Davies; Mary Eapen; Thomas G. Gross; Ayad A. Hussein; Margaret L. MacMillan; Parinda A. Mehta; Michael A. Pulsipher; Adriana Seber; Ann E. Woolfrey; Haydar A. Frangoul; Paul A. Carpenter

doi:10.1016/j.bbmt.2011.05.014

Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

Eneida R. Nemecek, Kristin Ellis, Wensheng He, Nancy J. Bunin, Rajinder S. Bajwa, Alexandra Cheerva, Mitchell S. Cairo, Christopher Dvorak, Michel Duval, Stella Davies, Mary Eapen, Thomas G. Gross, Ayad A. Hussein, Margaret L. MacMillan, Parinda A. Mehta, Michael A. Pulsipher, Adriana Seber, Ann E. Woolfrey, Haydar A. Frangoul, Paul A. Carpenter

Pediatric Blood & Marrow Transplant & Cellular Therapy

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

Original language	English (US)
Pages (from-to)	1833-1840
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	17
Issue number	12
DOIs	https://doi.org/10.1016/j.bbmt.2011.05.014
State	Published - Dec 2011

Bibliographical note

Funding Information:
Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) ; Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; Contract HHSH234200637015C from the Health Resources and Services Administration ; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB, Allos Inc, Amgen Inc , an anonymous donation to the Medical College of Wisconsin, Astellas Pharma US Inc, Be the Match Foundation, Biogen IDEC, BioMarin Pharmaceutical Inc, Biovitrum AB, Blood Center of Wisconsin, Blue Cross and Blue Shield Association, Bone Marrow Foundation, Buchanan Family Foundation, CaridianBCT, Celgene Corporation, CellGenix, ClinImmune Labs, CTI Clinical Trial and Consulting Services, Eisai Inc, Genentech Inc, Genzyme Corporation, Histogenetics Inc, HKS Medical Information Systems, Hospira Inc, Kirin Brewery Co Ltd, Merck & Company, Medical College of Wisconsin, Millennium Pharmaceuticals Inc, Miller Pharmacal Group, Milliman USA Inc, Miltenyi Biotec Inc, National Marrow Donor Program, Nature Publishing Group, Novartis Oncology, Oncology Nursing Society, Osiris Therapeutics Inc, Otsuka America Pharmaceutical Inc, Pall Life Sciences, Pfizer Inc, Schering Corporation, Sigma-Tau Pharmaceuticals, Soligenix Inc, StemCyte Inc, StemSoft Software Inc, Sysmex America Inc, THERAKOS Inc, Vidacare Corporation, ViraCor Laboratories, ViroPharma Inc, and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government. The authors have no conflicts of interest to disclose.

Keywords

Advanced ALL
BMT
HCT
Nonrelapse mortality

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.bbmt.2011.05.014

Find It

Find It at U of M Libraries

Cite this

Nemecek, E. R., Ellis, K., He, W., Bunin, N. J., Bajwa, R. S., Cheerva, A., Cairo, M. S., Dvorak, C., Duval, M., Davies, S., Eapen, M., Gross, T. G., Hussein, A. A., MacMillan, M. L., Mehta, P. A., Pulsipher, M. A., Seber, A., Woolfrey, A. E., Frangoul, H. A., & Carpenter, P. A. (2011). Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biology of Blood and Marrow Transplantation, 17(12), 1833-1840. https://doi.org/10.1016/j.bbmt.2011.05.014

Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. / Nemecek, Eneida R.; Ellis, Kristin; He, Wensheng et al.
In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 12, 12.2011, p. 1833-1840.

Research output: Contribution to journal › Article › peer-review

Nemecek, ER, Ellis, K, He, W, Bunin, NJ, Bajwa, RS, Cheerva, A, Cairo, MS, Dvorak, C, Duval, M, Davies, S, Eapen, M, Gross, TG, Hussein, AA, MacMillan, ML, Mehta, PA, Pulsipher, MA, Seber, A, Woolfrey, AE, Frangoul, HA & Carpenter, PA 2011, 'Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission', Biology of Blood and Marrow Transplantation, vol. 17, no. 12, pp. 1833-1840. https://doi.org/10.1016/j.bbmt.2011.05.014

@article{f571b8f1a2c74f4aa2aa62ab09a26bfa,

title = "Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission",

abstract = "We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.",

keywords = "Advanced ALL, BMT, HCT, Nonrelapse mortality",

author = "Nemecek, {Eneida R.} and Kristin Ellis and Wensheng He and Bunin, {Nancy J.} and Bajwa, {Rajinder S.} and Alexandra Cheerva and Cairo, {Mitchell S.} and Christopher Dvorak and Michel Duval and Stella Davies and Mary Eapen and Gross, {Thomas G.} and Hussein, {Ayad A.} and MacMillan, {Margaret L.} and Mehta, {Parinda A.} and Pulsipher, {Michael A.} and Adriana Seber and Woolfrey, {Ann E.} and Frangoul, {Haydar A.} and Carpenter, {Paul A.}",

note = "Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) ; Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; Contract HHSH234200637015C from the Health Resources and Services Administration ; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB, Allos Inc, Amgen Inc , an anonymous donation to the Medical College of Wisconsin, Astellas Pharma US Inc, Be the Match Foundation, Biogen IDEC, BioMarin Pharmaceutical Inc, Biovitrum AB, Blood Center of Wisconsin, Blue Cross and Blue Shield Association, Bone Marrow Foundation, Buchanan Family Foundation, CaridianBCT, Celgene Corporation, CellGenix, ClinImmune Labs, CTI Clinical Trial and Consulting Services, Eisai Inc, Genentech Inc, Genzyme Corporation, Histogenetics Inc, HKS Medical Information Systems, Hospira Inc, Kirin Brewery Co Ltd, Merck & Company, Medical College of Wisconsin, Millennium Pharmaceuticals Inc, Miller Pharmacal Group, Milliman USA Inc, Miltenyi Biotec Inc, National Marrow Donor Program, Nature Publishing Group, Novartis Oncology, Oncology Nursing Society, Osiris Therapeutics Inc, Otsuka America Pharmaceutical Inc, Pall Life Sciences, Pfizer Inc, Schering Corporation, Sigma-Tau Pharmaceuticals, Soligenix Inc, StemCyte Inc, StemSoft Software Inc, Sysmex America Inc, THERAKOS Inc, Vidacare Corporation, ViraCor Laboratories, ViroPharma Inc, and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government. The authors have no conflicts of interest to disclose.",

year = "2011",

month = dec,

doi = "10.1016/j.bbmt.2011.05.014",

language = "English (US)",

volume = "17",

pages = "1833--1840",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

AU - Nemecek, Eneida R.

AU - Ellis, Kristin

AU - He, Wensheng

AU - Bunin, Nancy J.

AU - Bajwa, Rajinder S.

AU - Cheerva, Alexandra

AU - Cairo, Mitchell S.

AU - Dvorak, Christopher

AU - Duval, Michel

AU - Davies, Stella

AU - Eapen, Mary

AU - Gross, Thomas G.

AU - Hussein, Ayad A.

AU - MacMillan, Margaret L.

AU - Mehta, Parinda A.

AU - Pulsipher, Michael A.

AU - Seber, Adriana

AU - Woolfrey, Ann E.

AU - Frangoul, Haydar A.

AU - Carpenter, Paul A.

N1 - Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) ; Grant/Cooperative Agreement 5U01HL069294 from the NHLBI and NCI ; Contract HHSH234200637015C from the Health Resources and Services Administration ; Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from AABB, Allos Inc, Amgen Inc , an anonymous donation to the Medical College of Wisconsin, Astellas Pharma US Inc, Be the Match Foundation, Biogen IDEC, BioMarin Pharmaceutical Inc, Biovitrum AB, Blood Center of Wisconsin, Blue Cross and Blue Shield Association, Bone Marrow Foundation, Buchanan Family Foundation, CaridianBCT, Celgene Corporation, CellGenix, ClinImmune Labs, CTI Clinical Trial and Consulting Services, Eisai Inc, Genentech Inc, Genzyme Corporation, Histogenetics Inc, HKS Medical Information Systems, Hospira Inc, Kirin Brewery Co Ltd, Merck & Company, Medical College of Wisconsin, Millennium Pharmaceuticals Inc, Miller Pharmacal Group, Milliman USA Inc, Miltenyi Biotec Inc, National Marrow Donor Program, Nature Publishing Group, Novartis Oncology, Oncology Nursing Society, Osiris Therapeutics Inc, Otsuka America Pharmaceutical Inc, Pall Life Sciences, Pfizer Inc, Schering Corporation, Sigma-Tau Pharmaceuticals, Soligenix Inc, StemCyte Inc, StemSoft Software Inc, Sysmex America Inc, THERAKOS Inc, Vidacare Corporation, ViraCor Laboratories, ViroPharma Inc, and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government. The authors have no conflicts of interest to disclose.

PY - 2011/12

Y1 - 2011/12

N2 - We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

AB - We conducted a retrospective study of 155 children who underwent unrelated donor hematopoietic cell transplantation (HCT) between 1990 and 2005 for acute lymphoblastic leukemia in third remission. The median patient age was 11 years, the median time from diagnosis to first relapse was 36 months, and the median time from first relapse to second relapse was 26 months. Stem cell sources were bone marrow (n = 115), peripheral blood (n = 11), and cord blood (n = 29). All patients received a myeloablative pretransplantation conditioning regimen. The 5-year estimates of leukemia-free survival, relapse, and nonrelapse mortality were 30%, 25%, and 45%, respectively. In multivariate analysis, the only risk factor associated with relapse was the interval between the first relapse and the second relapse. Second relapses occurring >26 months from the first relapse were associated with lower risk for post-HCT relapse compared with second relapses occurring at ≤26 months (relative risk, 0.4; P =.01). Relapse risk was lowest when late second relapse was preceded by late first relapse (>36 months from diagnosis), as demonstrated by a 3-year relapse rate of 9% (P =.0009). Our data indicate that long-term leukemia-free survival can be achieved in children with acute lymphoblastic leukemia in third remission using unrelated donor HCT, especially when the second relapse occurs late.

KW - Advanced ALL

KW - BMT

KW - HCT

KW - Nonrelapse mortality

UR - http://www.scopus.com/inward/record.url?scp=81255161748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255161748&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.05.014

DO - 10.1016/j.bbmt.2011.05.014

M3 - Article

C2 - 21683798

AN - SCOPUS:81255161748

SN - 1083-8791

VL - 17

SP - 1833

EP - 1840

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 12

ER -

Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this